CEO of drugmaker GSK to step down by year's end
[September 29, 2025]
LONDON (AP) — GSK Chief Executive Emma Walmsley, the first woman
to lead a major pharmaceutical company, will step down Dec. 31 after
more than eight years at the head of the London-based drugmaker.
Walmsley, 56, will be replaced by Luke Miels, currently GSK’s chief
commercial officer, the company said in a statement released on Monday.
While GSK achieved a number of strategic successes under Walmsley,
including the spinoff of the consumer health care business Haleon, it
has disappointed investors. GSK’s shares rose 3.3% to 1534.50 pence in
early trading, making it the biggest gainer on the London Stock
Exchange.
GSK’s shares fell 11% between April 1, 2017, when Walmsley became CEO,
and last Friday.
[to top of second column]
|
 “Despite the progress, the share
price performance has been lackluster,” Derren Nathan, head of
equity research at U.K.-based Hargreaves Lansdown,” said in a note
to investors.
“Although her record of delivering on financial guidance has been
strong, the company’s growth rates remain stuck in single-digit
territory.”
All contents © copyright 2025 Associated Press. All rights reserved |
